Bibliography
- Kantarjian HM , CortesJE, O‘BrienS et al.: Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-α.Blood104(7) , 1979–1988 (2004).
- Druker BJ , GuilhotF, O‘BrienSG et al.: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.N. Engl. J. Med.355(23) , 2408–2417 (2006).
- Kantarjian H , GilesF, WunderleL et al.: Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.N. Engl. J. Med.354(24) , 2542–2551 (2006).
- Hochhaus A , KantarjianHM, BaccaraniM et al.: Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.Blood109(6) , 2303–2309 (2007).
- Clark RE , DodiIA, HillSC et al.: Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein.Blood98(10) , 2887–2893 (2001).
- Makita M , AzumaT, HamaguchiH et al.: Leukemia-associated fusion proteins, DEK-CAN and BCR-ABL, represent immunogenic HLA-DR-restricted epitopes recognized by fusion peptide-specific CD4+ T lymphocytes.Leukemia16(12) , 2400–2407 (2002).
- Wagner WM , OuyangQ, PawelecG: The abl/bcr gene product as a novel leukemia-specific antigen: peptides spanning the fusion region of abl/bcr can be recognized by both CD4+ and CD8+ T lymphocytes.Cancer Immunol. Immunother.52(2) , 89–96 (2003).
- Rojas JM , KnightK, WangL, ClarkRE: Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study.Leukemia21(11) , 2287–2295 (2007).
- Kolb HJ : Graft-versus-leukemia effects of transplantation and donor lymphocytes.Blood112(12) , 4371–4383 (2008).
- Smit WM , RijnbeekM, van Bergen CA, Fibbe WE, Willemze R, Falkenburg JH: T cells recognizing leukemic CD34+ progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation. Proc. Natl Acad. Sci. USA95(17) , 10152–10157 (1998).
- Grabrucker C , LiepertA, DreyigJ et al.: The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells.J. Immunother.33(5) , 523–537 (2010).
- Liepert A , GrabruckerC, KremserA et al.: Quality of T-cells after stimulation with leukemia-derived dendritic cells (DC) from patients with acute myeloid leukemia (AML) or myeloid dysplastic syndrome (MDS) is predictive for their leukemia cytotoxic potential.Cell Immunol.265(1) , 23–30 (2010).
- Ossenkoppele GJ , StamAG, WestersTM et al.: Vaccination of chronic myeloid leukemia patients with autologous in vitro cultured leukemic dendritic cells.Leukemia17(7) , 1424–1426 (2003).
- Westermann J , KoppJ, vanLA et al.: Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia.Br. J. Haematol.137(4) , 297–306 (2007).
- Schmitt M , LiL, GiannopoulosK et al.: Chronic myeloid leukemia cells express tumor-associated antigens eliciting specific CD8+ T-cell responses and are lacking costimulatory molecules.Exp. Hematol.34(12) , 1709–1719 (2006).
- Dong R , CwynarskiK, EntwistleA et al.: Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration.Blood101(9) , 3560–3567 (2003).
- Westers TM , JanssenJJ, HoutenbosI, SnoijsNC, van de Loosdrecht AA, Ossenkoppele GJ: Maintained immunogenicity of chronic myeloid leukemia-derived dendritic cells in the presence of Imatinib mesylate: implication for vaccination regimens. Leukemia20 , 154–157 (2006).
- Eisendle K , LangA, EiblB et al.: Phenotypic and functional deficiencies of leukaemic dendritic cells from patients with chronic myeloid leukaemia.Br. J. Haematol.120(1) , 63–73 (2003).
- Lee JJ , KookH, ParkMS et al.: Immunotherapy using autologous monocyte-derived dendritic cells pulsed with leukemic cell lysates for acute myeloid leukemia relapse after autologous peripheral blood stem cell transplantation.J. Clin. Apheresis19(2) , 66–70 (2004).
- Zeng Y , GranerMW, FengH, LiG, KatsanisE: Imatinib mesylate effectively combines with chaperone-rich cell lysate-loaded dendritic cells to treat bcr-abl+ murine leukemia.Int. J. Cancer110(2) , 251–259 (2004).
- van den Ancker W , van Luijn MM, Ruben JM et al.: Targeting Toll-like receptor 7/8 enhances uptake of apoptotic leukemic cells by monocyte-derived dendritic cells but interferes with subsequent cytokine-induced maturation. Cancer Immunol. Immunother.60(1) , 37–47 (2011).
- Weigel BJ , Panoskaltsis-MortariA, DiersM et al.: Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses.Exp. Hematol.34(10) , 1403–1412 (2006).
- Westers TM , HoutenbosI, van de Loosdrecht AA, Ossenkoppele GJ: Divergent autologous T cell responses to leukaemic dendritic cells during remission in acute promyelocytic leukaemia. Cell Oncol.27(4) , 261–266 (2005).
- Westers TM , HoutenbosI, SchuurhuisGJ, OssenkoppeleGJ, van de Loosdrecht AA: Quantification of T-cell-mediated apoptosis in heterogeneous leukemia populations using four-color multiparameter flow cytometry. Cytometry A66(1) , 71–77 (2005).
- van den Ancker W , van Luijn MM, Westers TM et al.: Recent advances in antigen-loaded dendritic cell-based strategies for treatment of minimal residual disease in acute myeloid leukemia. Immunotherapy2(1) , 69–83 (2010).
- Roskrow MA , DillooD, SuzukiN, ZhongW, RooneyCM, BrennerMK: Autoimmune disease induced by dendritic cell immunization against leukemia.Leuk. Res.23(6) , 549–557 (1999).
- Li L , GiannopoulosK, ReinhardtP et al.: Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts.Int. J. Oncol.28(4) , 855–861 (2006).
- Schui DK , SinghL, SchneiderB, KnauA, HoelzerD, WeidmannE: Inhibiting effects on the induction of cytotoxic T lymphocytes by dendritic cells pulsed with lysates from acute myeloid leukemia blasts.Leuk. Res.26(4) , 383–389 (2002).
- Galea-Lauri J , WellsJW, DarlingD, HarrisonP, FarzanehF: Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.Cancer Immunol. Immunother.53(11) , 963–977 (2004).
- Motta JM , NascimentoCR, RumjanekVM: Leukemic cell products down-regulate human dendritic cell differentiation.Cancer Immunol. Immunother.59(11) , 1645–1653 (2010).
- de Vries IJ , LesterhuisWJ, BarentszJO et al.: Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy.Nat. Biotechnol.23(11) , 1407–1413 (2005).
- Sloma I , JiangX, EavesAC, EavesCJ: Insights into the stem cells of chronic myeloid leukemia.Leukemia24(11) , 1823–1833 (2010).
- Holyoake T , JiangX, EavesC, EavesA: Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia.Blood94(6) , 2056–2064 (1999).
- Graham SM , JorgensenHG, AllanE et al.: Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro.Blood99(1) , 319–325 (2002).
- Copland M , HamiltonA, ElrickLJ et al.: Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.Blood107(11) , 4532–4539 (2006).
- Jorgensen HG , AllanEK, JordanidesNE, MountfordJC, HolyoakeTL: Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells.Blood109(9) , 4016–4019 (2007).
- Syme R , BryanT, DugganP, BajwaR, StewartD, GluckS: Priming with dendritic cells can generate strong cytotoxic T cell responses to chronic myelogenous leukemia cells in vitro.Stem Cells Dev.13(2) , 211–221 (2004).
- Decker WK , XingD, LiS et al.: Double loading of dendritic cell MHC class I and MHC class II with an AML antigen repertoire enhances correlates of T-cell immunity in vitro via amplification of T-cell help.Vaccine24(16) , 3203–3216 (2006).
- Lemoli RM , SalvestriniV, BianchiE et al.: Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib.Blood114(25) , 5191–5200 (2009).
- Janssen JJWM , DeenikW, SmoldersKGM et al.: A new flow cytometry-based method to discriminate malignant from normal stem cells in chronic myeloid leukemia.Blood Abstract 114, 3245 (2009).